Economic Analysis of Pharmacogenomic-Guided Clopidogrel Treatment in Serbian Patients with Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention

References

• Niitsu Y , JakubowskiJA , SugidachiA , AsaiF . Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity . Semin. Thromb. Hemost.31 , 184 – 194 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Task force for STEMI . www.colorado.gov/pacific/cdphe/stemi-task-force .
   Google Scholar
• Mehta SR , TanguayJF , EikelboomJWet al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial . Lancet376 , 1233 – 1243 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Scott SA , SangkuhlK , SteinCMet al. Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update . Clin. Pharmacol. Ther.94 ( 3 ), 317 – 323 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Sibbing D , KochW , GebhardDet al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement . Circulation121 ( 4 ), 512 – 518 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Mizzi C , DalabiraE , KumuthiniJet al. A European spectrum of pharmacogenomic biomarkers: implications for clinical pharmacogenomics . PLoS ONE11 ( 9 ), e0162866 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Snyder S , MitropoulouC , PatrinosGP , WilliamsMC . Economic evaluation of pharmacogenomics: a value-based approach to pragmatic decision making in the face of complexity . Public Health Genomics17 ( 5–6 ), 256 – 264 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Mitropoulou C , FragoulakisV , BozinaNet al. Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke . Pharmacogenomics16 ( 2 ), 137 – 148 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Van de Werf F , ArdissinoD , BetriuAet al. Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The task force on the management of acute myocardial infarction of the European Society of Cardiology . Eur. Heart J.24 , 28 – 66 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Cutlip DE , WindeckerS , MehranRet al. Clinical end points in coronary stent trials: a case for standardized definitions . Circulation115 ( 17 ), 2344 – 2351 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Van de Werf F , BaxJ , BetriuAet al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology . Eur. Heart J.29 , 2909 – 2945 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Desgagne A , CastillouxAM , AngersJF , LeLorierJ . The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data . Pharmacoeconomics3 ( 5 Pt 1 ), 487 – 497 ( 1998 ).
   Google Scholar
• Fragoulakis V , KourlabaG , TarlatzisB , MastrominasM , ManiadakisN . Economic evaluation of alternative assisted reproduction techniques in management of infertility in Greece . Clinicoecon. Outcomes Res.4 , 185 – 192 ( 2012 ).
   PubMedGoogle Scholar
• Sorich MJ , WieseMD , O’SheaRL , PekarskyB . Review of the cost effectiveness of pharmacogenetic-guided treatment of hypercholesterolaemia . Pharmacoeconomics31 ( 5 ), 377 – 391 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Patel V , LinFJ , OjoOet al. Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention . Pharm. Pract. (Granada)12 ( 3 ), 438 ( 2014 ).
   PubMedGoogle Scholar
• O’Donoghue M , AntmanEM , BraunwaldEet al. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis . J. Am. Coll. Cardiol.54 ( 8 ), 678 – 685 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Lala A , BergerJS , SharmaG , HochmanJS , Scott BraithwaiteR , LadapoJA . Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost–effectiveness analysis . J. Thromb. Haemost.11 ( 1 ), 81 – 91 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Reese ES , Daniel MullinsC , BeitelsheesAL , OnukwughaE . Cost–effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel . Pharmacotherapy32 ( 4 ), 323 – 332 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Wallentin L , JamesS , StoreyRFet al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial . Lancet376 ( 9749 ), 1320 – 1328 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Crespin DJ , FederspielJJ , BiddleAK , JonasDE , RossiJS . Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost–effectiveness analysis . Value Health14 ( 4 ), 483 – 491 ( 2011 ).
   PubMed Web of Science ®Google Scholar